

MARKET REPORT



Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs, and Over-the-Counter Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Technology (Biologics, Cell Therapy, Gene Th

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs, and Over-the-Counter Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Technology (Biologics, Cell Therapy, Gene Th

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs, and Over-the-Counter Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Technology (Biologics, Cell Therapy, Gene Th

Ophthalmic drugs are preparations used for the treatment of eye diseases and disorders such as cataract, glaucoma, color blindness, diabetic macular edema, CMV retinitis, and age-related macular degeneration. The ophthalmic drugs market is witnessing significant growth, due to increase in prevalence of eye disorders and rise in use of combination therapies for treatment of ophthalmic disorders, especially glaucoma. Combination therapies have various advantages over traditional medication such improvement in patient compliance and efficacy. Moreover, surge in prevalence of ophthalmic disorders, rise in geriatric population globally, and change in demographics fuel the ophthalmic drugs market growth. The global ophthalmic drugs market was valued at \$29,613 million in 2016, and is expected to reach \$42,663 million by 2023, registering a CAGR of 5.3% from 2017 to 2023.

The ophthalmic drugs market is segmented based on indication, type, distribution channel, dosage form, technology, therapeutic class, and geography. Depending on indication, the market is divided into dry eye, glaucoma, infection/inflammation/allergy, retinal disorders, and others. On the basis of type, the market is bifurcated into prescription drugs and over-the-counter drugs. By distribution channel, it is categorized into hospital pharmacies, online pharmacies, drug stores, and others. According to dosage form, it is classified into liquid ophthalmic drug forms, semisolid ophthalmic drug forms, solid ophthalmic drug forms, multicompartment drug delivery systems, and other ophthalmic drug forms. As per technology, the market is segmented into biologics, cell therapy, gene therapy, drug delivery, small molecule, and others. Based on therapeutic class, it is classified into anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, and anti-allergy drugs. Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

As per ophthalmic drugs market analysis, in the recent years, Asia-Pacific reported significant growth in the ophthalmic drugs market, owing to steady increase in the prevalence of glaucoma in the Asian population. In addition, increase in the number of people suffering from primary angle-closure glaucoma in Japan, China, and South Korea supplement this growth further.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global ophthalmic drugs market with the current trends and future estimations to elucidate the imminent investment pockets.

Comprehensive analysis of the factors that drive and restrict the market growth is provided.

Comprehensive quantitative analysis of the industry is provided from 2016 to 2023 to assist stakeholders to capitalize on the prevailing market opportunities.

Extensive analysis of the key segments of the industry helps in understanding the trends in types and technologies globally.

Key players and their strategies are provided to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS

By Indication

Dry Eye

Glaucoma

Infection/Inflammation/Allergy

Retinal Disorders

Wet Age-related Macular Degeneration

Dry Age-related Macular Degeneration

Diabetic Retinopathy

Others

Others

By Type

Prescription Drugs

Over-the-Counter Drugs

By Dosage Form

Liquid Ophthalmic Drug Forms

Solid Ophthalmic Drug Forms

Semisolid Ophthalmic Drug Forms

Multicompartment Drug Delivery Systems

Other Ophthalmic Drug Forms

By Technology

Biologics

Cell Therapy

Gene Therapy

Drug Delivery

Small Molecule

Others

By Distribution Channel

Hospital Pharmacies

Drug Stores

Online Pharmacies

Others

By Therapeutic Class

Anti-glaucoma

Anti-infection

Anti-inflammatory

Anti-allergy

By Geography

North America

U.S.

Canada

Mexico

Europe

UK

France

Germany

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

South Africa

Turkey

Saudi Arabia

Rest of LAMEA

KEY MARKET PLAYERS

Santen Pharmaceutical Co., Ltd.

Bausch & Lomb Inc. (Valeant Pharmaceuticals International, Inc.)

Shire Plc

Alcon (Novartis)

Genentech, Inc.

Allergan, Plc

Sun Pharmaceutical Industries Limited

Actavis Generics (Teva Pharmaceutical Industries Ltd.)

Regeneron Pharmaceuticals, Inc.

Pfizer Inc.

The other players in the value chain include (profiles not included in the report)

Abbott Medical Optics, Inc.

Carl-Zeiss AG

Ellex Medical Lasers Ltd.

Essilor International S.A.

Hoya Corporation

Insight Vision Inc.

Nidek Co. Ltd.

Novagali Pharma S A

Topcon Corporation

Ziemer Ophthalmic Systems AG

Additional Details

Publisher : Allied Market Research

Reference : LI 17310

Number of Pages : 351

Report Format : PDF

Publisher Information :



Allied Market Research
Diligent Intelligence - Improved Growth

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and Corporate Data

Best Prices Guaranteed

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs, and Over-the-Counter Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Technology (Biologics, Cell Therapy, Gene Th

- CHAPTER 1 INTRODUCTION1.1. REPORT DESCRIPTION1.2. KEY BENEFITS1.3. KEY MARKET SEGMENTS1.4. RESEARCH METHODOLOGY1.4.1. Secondary research1.4.2. Primary research1.4.3. Analyst tools & modelsCHAPTER 2 EXECUTIVE SUMMARY2.1. CXO PERSPECTIVECHAPTER 3 MARKET OVERVIEW3.1. MARKET DEFINITION AND SCOPE3.2. KEY FINDINGS3.2.1. Top investment pockets3.2.2. Top winning strategies3.3. PORTERS FIVE FORCES ANALYSIS3.4. MARKET SHARE ANALYSIS, 20163.5. MARKET DYNAMICS3.5.1. Drivers3.5.1.1. Increase in focus of key players to develop combination therapies for the treatment of ophthalmic disorders3.5.1.2. Rise in prevalence of ophthalmic disorders worldwide3.5.1.3. Change in the demographics across the globe3.5.2. Restraints3.5.2.1. Longer timelines required for the development of ophthalmic drugs3.5.2.2. Risk of side effects associated with ophthalmic drugs3.5.3. Opportunity3.5.3.1. Increase in investment by market players in the emerging economiesCHAPTER 4 OPHTHALMIC DRUGS MARKET, BY INDICATION4.1. OVERVIEW4.1.1. Market size and forecast4.2. DRY EYE4.2.1. Key market trends4.2.2. Growth factors and opportunities4.2.3. Market size and forecast4.3. GLAUCOMA4.3.1. Key market trends4.3.2. Growth factors and opportunities4.3.3. Market size and forecast4.4. INFECTION/INFLAMMATION/ALLERGY4.4.1. Key market trends4.4.2. Growth factors and opportunities4.4.3. Market size and forecast4.5. RETINAL DISORDERS4.5.1. Key market trends4.5.2. Growth factors and opportunities4.5.3. Market size and forecast4.5.4. Wet age-related macular degeneration4.5.4.1. Market size and forecast4.5.5. Dry age-related macular degeneration4.5.5.1. Market size and forecast4.5.6. Diabetic retinopathy4.5.6.1. Market size and forecast4.5.7. Others4.5.7.1. Market size and forecast4.6. OTHERS4.6.1. Key market trends4.6.2. Growth factors and opportunities4.6.3. Market size and forecastCHAPTER 5 OPHTHALMIC DRUGS MARKET, BY TYPE5.1. OVERVIEW5.1.1. Market size and forecast5.2. PRESCRIPTION DRUGS5.2.1. Market size and forecast5.3. OVER-THE-COUNTER DRUGS5.3.1. Market size and forecastCHAPTER 6 OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL6.1. OVERVIEW6.1.1. Market size and forecast6.2. HOSPITAL PHARMACIES6.2.1. Market size and forecast6.3. DRUG STORES6.3.1. Market size and forecast6.4. ONLINE PHARMACIES6.4.1. Market size and forecast6.5. OTHERS6.5.1. Market size and forecastCHAPTER 7 OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM7.1. OVERVIEW7.1.1. Market size and forecast7.2. LIQUID OPHTHALMIC DRUG FORMS7.2.1. Market size and forecast7.3. SEMISOLID OPHTHALMIC DRUG FORMS7.3.1. Market size and forecast7.4. SOLID OPHTHALMIC DRUG FORMS7.4.1. Market size and forecast7.5. MULTICOMPARTMENT DRUG DELIVERY SYSTEMS7.5.1. Market size and forecast7.6. OTHER OPHTHALMIC DRUG FORMS7.6.1. Market size and forecastCHAPTER 8 OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS8.1. OVERVIEW8.1.1. Market size and forecast8.2. ANTI-INFLAMMATORY8.2.1. Market size and forecast8.2.2. Nonsteroidal anti-inflammatory drugs (NSAIDs)8.2.3. Steroids8.3. ANTI-INFECTIVE8.3.1. Market size and forecast8.3.2. Antifungal drugs8.3.3. Antibacterial drugs8.3.4. Others8.4. ANTI-GLAUCOMA8.4.1. Market size and forecast8.4.2. Beta blockers8.4.3. Prostaglandin analogs8.4.4. Others8.5. ANTI-ALLERGY8.5.1. Market size and forecastCHAPTER 9 OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY9.1. OVERVIEW9.1.1. Market size and forecast9.2. BIOLOGICS9.2.1. Market size and forecast9.3. CELL THERAPY9.3.1. Market size and forecast9.4. GENE THERAPY9.4.1. Market size and forecast9.5. SMALL MOLECULE9.5.1. Market size and forecast9.6. DRUG DELIVERY9.6.1. Market size and forecast9.7. OTHERS9.7.1. Market size and forecastCHAPTER 10 OPHTHALMIC

DRUGS MARKET, BY REGION10.1. OVERVIEW10.1.1. Market size and forecast10.2. NORTH AMERICA10.2.1. Key market trends10.2.2. Key growth factors and opportunities10.2.3. Market size and forecast, by country10.2.4. Market size and forecast, by indication10.2.5. Market size and forecast, by type10.2.6. Market size and forecast, by technology10.2.7. Market size and forecast, by distribution channel10.2.8. Market size and forecast, by dosage form10.2.9. Market size and forecast, by therapeutic class10.2.9.1. U.S., by indication10.2.9.2. U.S., by type10.2.9.3. U.S., by distribution channel10.2.9.4. U.S., by dosage form10.2.9.5. U.S., by technology10.2.9.6. U.S., by therapeutic class10.2.9.7. Canada, by indication10.2.9.8. Canada, by type10.2.9.9. Canada, by distribution channel10.2.9.10. Canada, by dosage form10.2.9.11. Canada, by technology10.2.9.12. Canada, by therapeutic class10.2.9.13. Mexico, by indication10.2.9.14. Mexico, by type10.2.9.15. Mexico, by distribution channel10.2.9.16. Mexico, by dosage form10.2.9.17. Mexico, by technology10.2.9.18. Mexico, by therapeutic class10.3. EUROPE10.3.1. Key market trends10.3.2. Key growth factors and opportunities10.3.3. Europe Market size and forecast, by country10.3.4. Market size and forecast, by indication10.3.5. Market size and forecast, by type10.3.6. Market size and forecast, by technology10.3.7. Market size and forecast, by distribution channel10.3.8. Market size and forecast, by dosage form10.3.9. Market size and forecast, by therapeutic class10.3.9.1. Germany, by indication10.3.9.2. Germany, by type10.3.9.3. Germany, by distribution channel10.3.9.4. Germany, by dosage form10.3.9.5. Germany, by technology10.3.9.6. Germany, by therapeutic class10.3.9.7. France, by indication10.3.9.8. France, by type10.3.9.9. France, by distribution channel10.3.9.10. France, by dosage form10.3.9.11. France, by technology10.3.9.12. France, by therapeutic class10.3.9.13. UK, by indication10.3.9.14. UK, by type10.3.9.15. UK, by distribution channel10.3.9.16. UK, by dosage form10.3.9.17. UK, by technology10.3.9.18. UK, by therapeutic class10.3.9.19. Italy, by indication10.3.9.20. Italy, by type10.3.9.21. Italy, by distribution channel10.3.9.22. Italy, by dosage form10.3.9.23. Italy, by technology10.3.9.24. Italy, by therapeutic class10.3.9.25. Spain, by indication10.3.9.26. Spain, by type10.3.9.27. Spain, by distribution channel10.3.9.28. Spain, by dosage form10.3.9.29. Spain, by technology10.3.9.30. Spain, by therapeutic class10.3.9.31. Rest of Europe, by indication10.3.9.32. Rest of Europe, by type10.3.9.33. Rest of Europe, by distribution channel10.3.9.34. Rest of Europe, by dosage form10.3.9.35. Rest of Europe, by technology10.3.9.36. Rest of Europe, by therapeutic class10.4. ASIA-PACIFIC10.4.1. Key market trends10.4.2. Key growth factors and opportunities10.4.3. Asia-Pacific Market size and forecast, by country10.4.4. Market size and forecast, by indication10.4.5. Market size and forecast, by type10.4.6. Market size and forecast, by technology10.4.7. Market size and forecast, by distribution channel10.4.8. Market size and forecast, by dosage form10.4.9. Market size and forecast, by therapeutic class10.4.9.1. Japan, by indication10.4.9.2. Japan, by type10.4.9.3. Japan, by distribution channel10.4.9.4. Japan, by dosage form10.4.9.5. Japan, by technology10.4.9.6. Japan, by therapeutic class10.4.9.7. China, by indication10.4.9.8. China, by type10.4.9.9. China, by distribution channel10.4.9.10. China, by dosage form10.4.9.11. China, by technology10.4.9.12. China, by therapeutic class10.4.9.13. India, by indication10.4.9.14. India, by type10.4.9.15. India, by distribution channel10.4.9.16. India, by dosage form10.4.9.17. India, by technology10.4.9.18. India, by therapeutic class10.4.9.19. Australia, by indication10.4.9.20. Australia, by type10.4.9.21. Australia, by distribution channel10.4.9.22. Australia, by dosage form10.4.9.23. Australia, by technology10.4.9.24. Australia, by therapeutic class10.4.9.25. South Korea, by indication10.4.9.26. South Korea, by type10.4.9.27. South Korea, by distribution channel10.4.9.28. South Korea, by dosage form10.4.9.29. South Korea, by technology10.4.9.30. South Korea, by therapeutic class10.4.9.31. Rest of Asia-Pacific, by indication10.4.9.32. Rest of Asia-Pacific, by type10.4.9.33. Rest of Asia-Pacific, by distribution channel10.4.9.34. Rest of Asia-Pacific, by dosage form10.4.9.35. Rest of Asia-Pacific, by technology10.4.9.36. Rest of Asia-Pacific, by therapeutic class10.5. LAMEA10.5.1. Key market trends10.5.2. Key growth factors and opportunities10.5.3. LAMEA Market size and forecast, by country10.5.4. Market size and forecast, by indication10.5.5. Market size and forecast, by type10.5.6. Market size and forecast, by technology10.5.7. Market size and forecast, by distribution channel10.5.8. Market size and forecast, by dosage form10.5.9. Market size and forecast, by therapeutic class10.5.9.1. Brazil, by indication10.5.9.2. Brazil, by type10.5.9.3. Brazil, by distribution channel10.5.9.4. Brazil, by dosage form10.5.9.5. Brazil, by technology10.5.9.6. Brazil, by therapeutic class10.5.9.7. South Africa, by indication10.5.9.8. South Africa, by type10.5.9.9. South Africa, by distribution channel10.5.9.10. South Africa, by dosage form10.5.9.11. South Africa, by technology10.5.9.12. South Africa, by therapeutic class10.5.9.13. Turkey, by indication10.5.9.14. Turkey, by type10.5.9.15. Turkey, by distribution channel10.5.9.16. Turkey, by dosage form10.5.9.17. Turkey, by technology10.5.9.18. Turkey, by therapeutic class10.5.9.19. Saudi Arabia, by indication10.5.9.20. Saudi Arabia, by type10.5.9.21. Saudi Arabia, by distribution channel10.5.9.22. Saudi Arabia, by dosage form10.5.9.23. Saudi Arabia, by technology10.5.9.24. Saudi Arabia, by therapeutic class10.5.9.25. Rest of LAMEA, by indication10.5.9.26. Rest of LAMEA, by type10.5.9.27. Rest of LAMEA, by distribution

channel10.5.9.28. Rest of LAMEA, by dosage form10.5.9.29. Rest of LAMEA, by technology10.5.9.30. Rest of LAMEA, by therapeutic class

CHAPTER 11 COMPANY PROFILES

11.1. ALLERGAN PLC

11.1.1. Company overview

11.1.2. Company snapshot

11.1.3. Operating business segments

11.1.4. Product portfolio

11.1.5. Business performance

11.1.6. Key strategic moves and developments

11.2. F. HOFFMANN-LA ROCHE AG (GENENTECH, INC.)

11.2.1. Company overview

11.2.2. Company snapshot

11.2.3. Operating business segments

11.2.4. Product portfolio

11.2.5. Business performance

11.2.6. Key strategic moves and developments

11.3. NOVARTIS AG (ALCON-A DIVISION OF NOVARTIS)

11.3.1. Company overview

11.3.2. Company snapshot

11.3.3. Operating business segments

11.3.4. Product portfolio

11.3.5. Business performance

11.3.6. Key strategic moves and developments

11.4. PFIZER INC.

11.4.1. Company overview

11.4.2. Company snapshot

11.4.3. Operating business segments

11.4.4. Product portfolio

11.4.5. Business performance

11.4.6. Key strategic moves and developments

11.5. REGENERON PHARMACEUTICALS INC.

11.5.1. Company overview

11.5.2. Company snapshot

11.5.3. Operating business segments

11.5.4. Product portfolio

11.5.5. Business performance

11.5.6. Key strategic moves and developments

11.6. SANTEN PHARMACEUTICAL CO., LTD.

11.6.1. Company overview

11.6.2. Company snapshot

11.6.3. Operating business segments

11.6.4. Product portfolio

11.6.5. Business performance

11.6.6. Key strategic moves and developments

11.7. SHIRE PLC

11.7.1. Company overview

11.7.2. Company snapshot

11.7.3. Operating business segments

11.7.4. Product portfolio

11.7.5. Business performance

11.7.6. Key strategic moves and developments

11.8. SUN PHARMACEUTICAL INDUSTRIES LIMITED

11.8.1. Company overview

11.8.2. Company snapshot

11.8.3. Operating business segments

11.8.4. Product portfolio

11.8.5. Business performance

11.8.6. Key strategic moves and developments

11.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.(ACTAVIS GENERICS)

11.9.1. Company overview

11.9.2. Company snapshot

11.9.3. Operating business segments

11.9.4. Product portfolio

11.9.5. Business performance

11.9.6. Key strategic moves and developments

11.10. VALEANT PHARMACEUTICAL INTERNATIONAL, INC. (BAUSCH & LOMB INC.)

11.10.1. Company overview

11.10.2. Company snapshot

11.10.3. Operating business segments

11.10.4. Product portfolio

11.10.5. Business performance

11.10.6. Key strategic moves and developments

List Of Tables in Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs, and Over-the-Counter Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Technology (Biologics, Cell Therapy, Gene Th

TABLE 1. NOVARTIS OPHTHALMOLOGIC PIPELINE PORTFOLIO, JULY 2011

TABLE 2. GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 3. OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY REGION, 2016-2023 (\$MILLION)

TABLE 4. OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY REGION, 2016-2023 (\$MILLION)

TABLE 5. OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY, BY REGION, 2016-2023 (\$MILLION)

TABLE 6. OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY REGION, 2016-2023 (\$MILLION)

TABLE 7. OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY TYPE, 2016-2023 (\$MILLION)

TABLE 8. OPHTHALMIC DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2016-2023 (\$MILLION)

TABLE 9. OPHTHALMIC DRUGS MARKET FOR DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2016-2023 (\$MILLION)

TABLE 10. OPHTHALMIC DRUGS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2016-2023 (\$MILLION)

TABLE 11. OPHTHALMIC DRUGS MARKET FOR OTHER, BY REGION, 2016-2023 (\$MILLION)

TABLE 12. OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016-2023 (\$MILLION)

TABLE 13. GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 14. PRESCRIPTION OPHTHALMIC DRUGS OFFERED BY BAUSCH + LOMB

TABLE 15. PRESCRIPTION OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 16. OPHTHALMIC DRUGS AVAILABLE OVER THE COUNTER FOR THE TREATMENT OF DRY EYE

TABLE 17. OVER-THE-COUNTER OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 18. GLOBAL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 19. OPHTHALMIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2016-2023 (\$MILLION)

TABLE 20. OPHTHALMIC DRUGS MARKET FOR DRUG STORES, BY REGION, 2016-2023 (\$MILLION)

TABLE 21. OPHTHALMIC DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2016-2023 (\$MILLION)

TABLE 22. OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016-2023 (\$MILLION)

TABLE 23. GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 24. OPHTHALMIC DRUGS ADMINISTERED IN LIQUID FORMS

TABLE 25. LIQUID OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 26. OPHTHALMIC DRUGS ADMINISTERED IN SEMISOLID FORMS

TABLE 27. SEMISOLID OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 28. VARIOUS TYPES OF SOLID OPHTHALMIC DRUG FORMS

TABLE 29. SOLID OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 30. MULTICOMPARTMENT DRUG DELIVERY SYSTEMS MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 31. OTHER OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 32. GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 33. OPHTHALMIC DRUGS MARKET FOR ANTI-INFLAMMATORY, BY REGION, 2016-2023 (\$MILLION)

TABLE 34. OPHTHALMIC DRUGS MARKET FOR ANTI-INFECTIVE, BY REGION, 2016-2023 (\$MILLION)

TABLE 35. OPHTHALMIC DRUGS MARKET FOR ANTI-GLAUCOMA, BY REGION, 2016-2023 (\$MILLION)

TABLE 36. OPHTHALMIC DRUGS MARKET FOR ANTI-ALLERGY, BY REGION, 2016-2023 (\$MILLION)

TABLE 37. GLOBAL OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 38. FDA-APPROVED OCULAR BIOLOGICS

TABLE 39. OPHTHALMIC DRUGS MARKET FOR BIOLOGICS, BY REGION, 2016-2023 (\$MILLION)

TABLE 40. OPHTHALMIC DRUGS MARKET FOR CELL THERAPY, BY REGION, 2016-2023 (\$MILLION)

TABLE 41. OPHTHALMIC DRUGS MARKET FOR GENE THERAPY, BY REGION, 2016-2023 (\$MILLION)

TABLE 42. OPHTHALMIC DRUGS MARKET FOR SMALL MOLECULE, BY REGION, 2016-2023 (\$MILLION)

TABLE 43. OPHTHALMIC DRUGS MARKET FOR DRUG DELIVERY, BY REGION, 2016-2023 (\$MILLION)

TABLE 44. OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016-2023 (\$MILLION)

TABLE 45. OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 46. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 47. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 48. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 49. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 50. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 51. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 52. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 53. U.S. OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 54. U.S. OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 55. U.S. OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 56. U.S. OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 57. U.S. OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 58. U.S. OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 59. CANADA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 60. CANADA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 61. CANADA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 62. CANADA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 63. CANADA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 64. CANADA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 65. MEXICO OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 66. MEXICO OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 67. MEXICO OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 68. MEXICO OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 69. MEXICO OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 70. MEXICO OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 71. EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 72. EUROPE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 73. EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 74. EUROPE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 75. EUROPE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 76. EUROPE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 77. EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 78. GERMANY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 79. GERMANY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 80. GERMANY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 81. GERMANY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 82. GERMANY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 83. GERMANY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 84. FRANCE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 85. FRANCE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 86. FRANCE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 87. FRANCE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 88. FRANCE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 89. FRANCE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 90. UK OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 91. UK OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 92. UK OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 93. UK OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 94. UK OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 95. UK OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 96. ITALY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 97. ITALY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 98. ITALY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 99. ITALY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 100. ITALY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 101. ITALY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 102. SPAIN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 103. SPAIN OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 104. SPAIN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 105. SPAIN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 106. SPAIN OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 107. SPAIN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 108. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 109. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 110. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 111. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 112. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 113. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 114. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 115. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 116. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 117. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 118. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 119. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 120. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 121. JAPAN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 122. JAPAN OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 123. JAPAN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 124. JAPAN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 125. JAPAN OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 126. JAPAN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 127. CHINA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 128. CHINA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 129. CHINA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 130. CHINA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 131. CHINA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 132. CHINA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 133. INDIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 134. INDIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 135. INDIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 136. INDIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 137. INDIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 138. INDIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 139. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 140. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 141. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 142. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 143. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 144. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 145. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 146. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 147. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 148. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 149. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 150. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 151. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 152. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 153. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 154. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 155. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 156. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 157. LAMEA OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 158. LAMEA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 159. LAMEA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 160. LAMEA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 161. LAMEA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 162. LAMEA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 163. LAMEA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 164. BRAZIL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 165. BRAZIL OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 166. BRAZIL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 167. BRAZIL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 168. BRAZIL OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 169. BRAZIL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 170. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 171. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 172. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 173. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 174. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 175. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 176. TURKEY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 177. TURKEY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 178. TURKEY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 179. TURKEY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 180. TURKEY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 181. TURKEY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 182. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 183. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 184. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 185. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 186. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 187. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 188. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 (\$MILLION)

TABLE 189. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 190. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 (\$MILLION)

TABLE 191. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 (\$MILLION)

TABLE 192. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 (\$MILLION)

TABLE 193. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 (\$MILLION)

TABLE 194. ALLERGAN: COMPANY SNAPSHOT

TABLE 195. ALLERGEN: OPERATING SEGMENTS

TABLE 196. ALLERGAN: PRODUCT PORTFOLIO

TABLE 197. ROCHE: COMPANY SNAPSHOT

TABLE 198. ROCHE: OPERATING SEGMENT

TABLE 199. ROCHE: PRODUCT PORTFOLIO

TABLE 200. NOVARTIS: COMPANY SNAPSHOT

TABLE 201. NOVARTIS: OPERATING SEGMENTS

TABLE 202. NOVARTIS: PRODUCT PORTFOLIO

TABLE 203. PFIZER: COMPANY SNAPSHOT

TABLE 204. PFIZER: OPERATING SEGMENTS

TABLE 205. PFIZER: PRODUCT PORTFOLIO

TABLE 206. REGENERON: COMPANY SNAPSHOT

TABLE 207. REGENERON: PRODUCT PORTFOLIO

TABLE 208. SANTEN PHARMACEUTICAL: COMPANY SNAPSHOT

TABLE 209. SANTEN PHARMACEUTICAL: OPERATING SEGMENTS

TABLE 210. SANTEN PHARMACEUTICAL: PRODUCT PORTFOLIO

TABLE 211. SHIRE: COMPANY SNAPSHOT

TABLE 212. SHIRE: PRODUCT PORTFOLIO

TABLE 213. SUN PHARMA: COMPANY SNAPSHOT

TABLE 214. SUN PHARMA: OPERATING SEGMENTS

TABLE 215. SUN PHARMA: PRODUCT PORTFOLIO

TABLE 216. TEVA: COMPANY SNAPSHOT

TABLE 217. TEVA: OPERATING SEGMENTS

TABLE 218. TEVA: PRODUCT PORTFOLIO

TABLE 219. VALEANT: COMPANY SNAPSHOT

TABLE 220. VALEANT: OPERATING SEGMENTS

TABLE 221. VALEANT: PRODUCT PORTFOLIO

List Of Figures, Charts and Diagrams in Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs, and Over-the-Counter Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Technology (Biologics, Cell Therapy, Gene Th

FIGURE 1. GLOBAL OPHTHALMIC DRUGS MARKET SNAPSHOT, 2016-2023

FIGURE 2. OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023

FIGURE 3. MARKET SEGMENTATION

FIGURE 4. TOP INVESTMENT POCKETS

FIGURE 5. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)

FIGURE 6. TOTAL NUMBER OF STRATEGIES

FIGURE 7. TOP WINNING STRATEGIES: NATURE AND COMPANY

FIGURE 8. HIGH BARGAINING POWER OF BUYERS

FIGURE 9. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 10. HIGH THREAT OF NEW ENTRANTS

FIGURE 11. HIGH THREAT OF SUBSTITUTION

FIGURE 12. MODERATE COMPETITIVE RIVALRY

FIGURE 13. MARKET SHARE ANALYSIS, 2016

FIGURE 14. DRIVERS, RESTRAINTS, AND OPPORTUNITIES

FIGURE 15. PREVALENT CASES OF AMD IN THE U.S., 2010

FIGURE 16. GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016

FIGURE 17. ALLERGAN: NET SALES, 2014-2016 (\$MILLION)

FIGURE 18. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 19. ROCHE: NET-SALES, 2014-2016 (\$MILLION)

FIGURE 20. ROCHE: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 21. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

<https://www.bioportfolio.co.uk/product/152935>
bioportfolio97@gmail.com to order

FIGURE 22. NOVARTIS: NET SALES, 2014-2016 (\$MILLION)

FIGURE 23. NOVARTIS: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 24. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 25. ALCON: NET SALES, 2014-2016 (\$MILLION)

FIGURE 26. ALCON: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 27. PFIZER: NET SALES, 2014-2016 (\$MILLION)

FIGURE 28. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 29. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 30. REGENERON: NET SALES, 2014-2016 (\$MILLION)

FIGURE 31. SANTEN PHARMACEUTICAL: NET SALES, 2015-2017 (\$MILLION)

FIGURE 32. SANTEN PHARMACEUTICAL: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 33. SANTEN PHARMACEUTICAL: REVENUE SHARE BY PRODUCT CATEGORY, 2017 (%)

FIGURE 34. SANTEN PHARMACEUTICAL: REVENUE SHARE BY GEOGRAPHY, 2017(%)

FIGURE 35. SHIRE: NET SALES, 2014-2016 (\$MILLION)

FIGURE 36. SHIRE: REVENUE SHARE BY PRODUCT CATEGORY, 2016 (%)

FIGURE 37. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 38. SUN PHARMA: NET SALES, 2015-2017 (\$MILLION)

FIGURE 39. SUN PHARMA: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 40. SUN PHARMA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 41. TEVA: NET SALES, 2014-2016 (\$MILLION)

FIGURE 42. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 43. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 44. VALEANT: NET SALES, 2014-2016 (\$MILLION)

FIGURE 45. VALEANT: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 46. VALEANT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

How to Buy...

Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs, and Over-the-Counter Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Technology (Biologics, Cell Therapy, Gene Th

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/152935>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$5370** | Single User Price
- \$7800** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.